Getinge (DB:GTN) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

GTN Aktienübersicht

Getinge AB (publ) bietet Produkte und Lösungen für Operationssäle, Intensivstationen und Sterilisationsabteilungen.

GTN fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Belohnungen

45.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 12.75% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Analysten sind sich einig, dass der Aktienkurs um 22.5%

Risikoanalyse

Unbeständige Dividendenentwicklung

Getinge AB (publ) Wettbewerber

Carl Zeiss Meditec

XTRA:AFX

€7.6b

Eckert & Ziegler

XTRA:EUZ

€1.0b

Drägerwerk KGaA

XTRA:DRW3

€899.9m

Stratec

XTRA:SBS

€575.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Getinge
Historical stock prices
Current Share Price	kr16.50
52 Week High	kr21.65
52 Week Low	kr14.97
Beta	0.49
1 Month Change	-10.57%
3 Month Change	-9.99%
1 Year Change	-22.05%
3 Year Change	-45.97%
5 Year Change	21.91%
Change since IPO	51.33%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	GTN	DE Medical Equipment	DE Markt
7D	0.9%	3.6%	-0.2%
1Y	-22.0%	0.6%	3.5%

Rendite im Vergleich zur Industrie: GTN unter dem Niveau der Branche German Medical Equipment, die im vergangenen Jahr eine Rendite von -2.1% erzielte.

Rendite vs. Markt: GTN hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is GTN's price volatile compared to industry and market?
GTN volatility
GTN Average Weekly Movement	6.1%
Medical Equipment Industry Average Movement	4.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: GTN hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: GTNDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1904	11,862	Mattias Perjos	www.getinge.com

Getinge AB (publ) bietet Produkte und Lösungen für Operationssäle, Intensivstationen und Sterilisationsabteilungen an. Das Unternehmen ist in den Segmenten Acute Care Therapies, Life Science und Surgical Workflows tätig. Es bietet extrakorporale Membranoxygenierung, mechanische Beatmung, mechanische Kreislaufunterstützung, fortschrittliche Patientenüberwachung, ICU-Infrastrukturausrüstung, Patientenflussmanagement und Drainagelösungen.

Getinge AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Getinge im Vergleich zum Marktanteil des Unternehmens?
GTN grundlegende Statistiken
Marktanteil	€4.51b
Gewinn(TTM)	€200.65m
Umsatz(TTM)	€2.83b

22.5x

Kurs-Gewinn-Verhältnis

1.6x

Kurs-Umsatz-Verhältnis

Ist GTN zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
GTN Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr32.20b
Kosten der Einnahmen	kr17.59b
Bruttogewinn	kr14.61b
Sonstige Ausgaben	kr12.32b
Umsatz	kr2.29b

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Jul 18, 2024

Gewinn per Aktie (EPS)	8.39
Bruttomarge	45.37%
Nettogewinnspanne	7.10%
Schulden/Eigenkapital-Verhältnis	20.1%

Wie hat sich GTN auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.3%

Aktuelle Dividendenrendite

52%

Ausschüttungsquote

GTN Aktienübersicht

Belohnungen

Risikoanalyse

Getinge AB (publ) Wettbewerber

XTRA:AFX

€7.6b

XTRA:EUZ

€1.0b

XTRA:DRW3

€899.9m

XTRA:SBS

€575.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Investor sentiment deteriorates as stock falls 17%

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Dividend of kr4.40 announced

Recent updates

Investor sentiment deteriorates as stock falls 17%

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Dividend of kr4.40 announced

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Third quarter 2023 earnings released

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Second quarter 2023 earnings released

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Investor sentiment deteriorates as stock falls 16%

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

First quarter 2023 earnings released

Now 23% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Investor sentiment deteriorated over the past week

Getinge Revises Net Sales Guidance for the Full Year 2022

Independent Chairman recently bought €281k worth of stock

Insufficient new directors

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Upcoming dividend of kr4.00 per share

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)

Insufficient new directors

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Chief Commercial Officer recently bought €56k worth of stock

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)

Getinge AB Provides Sales Guidance for the Year 2021

Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency

Chief Commercial Officer recently bought €27k worth of stock

Chief Commercial Officer recently bought €27k worth of stock

First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020)

Director has left the company

Upcoming dividend of kr3.00 per share

Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019)

Erträge & Einnahmen